Therapy News and Research

RSS

Expensive new diabetes drugs don't necessarily produce better outcomes

The annual cost of prescription diabetes drugs nearly doubled to $12.5 billion between 2001 and 2007, according to a study by researchers at the Stanford University School of Medicine and the University of Chicago. The researchers say the findings raise questions about whether the higher cost actually translates into improved care and better outcomes.

28 Oct 2008

Cholesterol-lowering statins associated with lower risk of death from pneumonia

Individuals who take cholesterol-lowering statins before being hospitalized with pneumonia appear less likely to die within 90 days afterward, according to a report in the October 27 issue of Archives of Internal Medicine.

28 Oct 2008

Brain stimulation improves dexterity

Applying electrical stimulation to the scalp and the underlying motor regions of the brain could make you more skilled at delicate tasks. Research published today in the open access journal BMC Neuroscience shows that a non-invasive brain-stimulation technique, transcranial direct current stimulation (tDCS), is able to improve the use of a person's non-dominant hand.

28 Oct 2008

Nanocort demonstrates safety and good response in phase I/II trial for rheumatoid arthritis

Galapagos NV has announced that Nanocort has demonstrated safety as well as a faster and more pronounced decrease in rheumatoid arthritis disease symptoms compared to reference medication.

27 Oct 2008

Anxiety disorders latest worry in high blood pressure

Family doctors and psychiatrists should carefully monitor the heart health of patients with anxiety disorders, Dr. Simon Bacon told the Canadian Cardiovascular Congress 2008, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society. "People with anxiety disorders are four times more likely to develop high blood pressure (hypertension) over one year than those of us who are anxiety free," says Dr. Bacon, a Heart and Stroke Foundation researcher at the Montreal Heart Institute. "Hypertension is a leading risk factor for stroke and heart disease."

27 Oct 2008

New strategy to treat human infections caused by the yeast Candida albicans

Researchers at Georgetown University Medical Center (GUMC) have successfully tested a genetic strategy designed to improve treatment of human infections caused by the yeast Candida albicans, ranging from diaper rash, vaginitis, oral infections (or thrush which is common in HIV/AIDS patients), as well as invasive, blood-borne and life-threatening diseases.

27 Oct 2008

Sunesis Pharmaceuticals updates clinical data on Voreloxin in platinum-resistant ovarian cancer

Sunesis Pharmaceuticals, Inc. has announced a presentation of updated interim results from an ongoing Phase 2 clinical trial demonstrating that the Company's lead product candidate, voreloxin, shows promising efficacy and safety as a single agent in patients with platinum-resistant ovarian cancer.

27 Oct 2008

NanoBio demonstrates new topical approach to treating nail fungus that circumvents problems with current therapy

A novel topical therapy for nail fungus, NB-002, has demonstrated a new topical approach to healing nail fungus by penetrating skin pores and diffusing through the skin that surrounds the entire nail plate, according to a study conducted by NanoBio Corporation.

27 Oct 2008

New treatment guidelines for carpal tunnel syndrome

The American Academy of Orthopaedic Surgeons (AAOS) has approved and released an evidence-based clinical practice guideline on "The Treatment of Carpal Tunnel Syndrome."

27 Oct 2008

Seeing nanotubes targeting tumors in vivo

Carbon nanotubes have significant potential for delivering both imaging and therapeutic agents to tumors, but there is still a need to better quantify how well these rolled-up sheets of graphite can target tumors.

27 Oct 2008

Nanodiamond drug device could transform cancer treatment

A team of investigators at Northwestern University has developed a promising nanomaterial-based biomedical device that could be used to deliver chemotherapy drugs locally to sites where cancerous tumors have been surgically removed.

27 Oct 2008

The sooner the better when it comes to HIV/AIDS treatment

New research into HIV/AIDS therapy has found that starting treatment with drugs for the AIDS virus may be better sooner than later as victims are more than 70% less likely to die when they started taking cocktails of HIV drugs earlier than currently recommended.

27 Oct 2008

Exercise-induced fatigue in muscular dystrophies, study points to potential new therapies

A University of Iowa study suggests that the prolonged fatigue after mild exercise that occurs in people with many forms of muscular dystrophy is distinct from the inherent muscle weakness caused by the disease.

26 Oct 2008

Simple gene-based blood test, quicker, more accurate evaluation for cystic fibrosis

Researchers at National Jewish Health have identified a simple gene-based blood test that more accurately and quickly measures cystic fibrosis patients' response to therapy than current tests.

26 Oct 2008

Even minimally symptomatic obstructive sleep apnea increases cardiovascular risk

People with even minimally symptomatic obstructive sleep apnea (OSA) may be at increased risk for cardiovascular disease because of impaired endothelial function and increased arterial stiffness, according to a study from the Oxford Centre for Respiratory Medicine in the UK.

26 Oct 2008

New molecules with many branches will help unleash potential of nanotechnology

Materials science and the pharmaceutical industry could soon be revolutionized by emerging nanotechnologies based on designer molecules with long complex tree-and branch structures. Such molecules offer almost limitless scope for design of bespoke compounds for specific applications in disease therapy, for novel materials such as resins, as well as electronic displays, and energy storage. Almost every field involving design and synthesis of chemical compounds will be transformed by the arrival of technologies allowing nanoscale design of these branched molecules, known as hyperbranched polymers.

26 Oct 2008

NanoVibronix receives FDA clearance for PainShield diathermy device

NanoVibronix, a medical device company, announced that the US Food and Drug Administration (FDA) has granted 510K clearance to market PainShield MD, a diathermy device used to treat pain. PainShield is the first hands-free, patch-based diathermy device, thus allowing for an entirely new dimension in ultrasound treatment of pain and soft tissue healing. The PainShield consists of a disposable patch connected to a portable reusable driver and generates ultrasound waves to the desired area of the body.

23 Oct 2008

Leukaemia drug may reverse multiple sclerosis brain damage

Scientists in Britain say a drug which was developed to treat leukaemia may also be a powerful new weapon against multiple sclerosis (MS).

23 Oct 2008

ZymoGenetics presents interim Interleukin 21 phase 2 results in renal cell cancer

ZymoGenetics, Inc. presented interim results today from a Phase 2 clinical trial evaluating Interleukin 21 (IL-21) in combination with Nexavar (sorafenib) tablets in patients with metastatic renal cell cancer.

22 Oct 2008

Medtronic launches new device to improve minimally-invasive treatment of thoracic aortic aneurysms

Extending an unmatched record of innovation in the field of endovascular aortic repair, Medtronic, Inc., today announced the U.S. market launch of the Talent Thoracic Stent Graft on the Xcelerant Delivery System, which makes minimally-invasive treatment of thoracic aortic aneurysms easier to perform.

22 Oct 2008

Therapy News and Research

Expensive new diabetes drugs don't necessarily produce better outcomes

Cholesterol-lowering statins associated with lower risk of death from pneumonia

Brain stimulation improves dexterity

Nanocort demonstrates safety and good response in phase I/II trial for rheumatoid arthritis

Anxiety disorders latest worry in high blood pressure

New strategy to treat human infections caused by the yeast Candida albicans

Sunesis Pharmaceuticals updates clinical data on Voreloxin in platinum-resistant ovarian cancer

NanoBio demonstrates new topical approach to treating nail fungus that circumvents problems with current therapy

New treatment guidelines for carpal tunnel syndrome

Seeing nanotubes targeting tumors in vivo

Nanodiamond drug device could transform cancer treatment

The sooner the better when it comes to HIV/AIDS treatment

Exercise-induced fatigue in muscular dystrophies, study points to potential new therapies

Simple gene-based blood test, quicker, more accurate evaluation for cystic fibrosis

Even minimally symptomatic obstructive sleep apnea increases cardiovascular risk

New molecules with many branches will help unleash potential of nanotechnology

NanoVibronix receives FDA clearance for PainShield diathermy device

Leukaemia drug may reverse multiple sclerosis brain damage

ZymoGenetics presents interim Interleukin 21 phase 2 results in renal cell cancer

Medtronic launches new device to improve minimally-invasive treatment of thoracic aortic aneurysms

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News